About MTM Laboratories
MTM Laboratories is a company based in Tucson (United States) founded in 1999 by Peter Pack was acquired by Roche in July 2011. MTM Laboratories has raised $76.07 million across 8 funding rounds from investors including Roche, HBM Healthcare Investments and Wellington Partners Venture Capital. MTM Laboratories operates in a competitive market with competitors including Aindra, Teal Health, Femasys, Self-screen and OncoHealth, among others.
- Headquarter Tucson, United States
- Founders Peter Pack
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of MTM Laboratories
MTM Laboratories has successfully raised a total of $76.07M across 8 strategic funding rounds. The most recent funding activity was a Series C round of $9.82 million completed in November 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MTM Laboratories
MTM Laboratories has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, HBM Healthcare Investments and Wellington Partners Venture Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in early-stage healthcare startups.
|
Locked | Locked | Locked | |
|
Private equity and venture captial firm focused on healthcare sectors
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked |
Investor details for MTM Laboratories
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MTM Laboratories
Investment portfolio details for MTM Laboratories
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MTM Laboratories
Detailed financials for MTM Laboratories
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mtm Laboratories Comparisons
Peer comparison for MTM Laboratories
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MTM Laboratories
MTM Laboratories operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aindra, Teal Health, Femasys, Self-screen and OncoHealth, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-powered systems for cervical cancer detection are provided.
|
|
| Locked | Locked | Locked |
Cervical cancer screening kits are provided by Teal Health.
|
|
| Locked | Locked | Locked |
Medical devices for women's healthcare are developed and provided.
|
|
| Locked | Locked | Locked |
Provider of self-screening solutions for cervical cancer
|
|
| Locked | Locked | Locked |
OncoHealth is focused on delivering oncology-focused digital health solutions.
|
Detailed competitors of MTM Laboratories
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mtm Laboratories
Complete news archive for MTM Laboratories
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MTM Laboratories
MTM Laboratories was founded in 1999.
MTM Laboratories is headquartered in Tucson, United States. It is registered at Tucson, Arizona, United States.
Peter Pack is the current CEO of MTM Laboratories. They have also founded this company.
MTM Laboratories is a funded company, having raised a total of $76.07M across 8 funding rounds to date.
MTM laboratories is a manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. It markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer CINtec p16 (E6H4) immunochemistry detects the over-expression of the cellular protein p16INK4a in cervical tissue and cytology specimens correlated with high-risk HPV-mediated oncogenic transformation. The company was acquired by Ventana (Roche group company) in 2011.
MTM Laboratories's top competitors include Femasys, OncoHealth and Aindra.
MTM Laboratories has 10 investors. Key investors include Roche, HBM Healthcare Investments, Wellington Partners Venture Capital, Gilde Healthcare, and Heidelberg Innovationsfonds Management.